SINGAPORE, July 14 -- A drug developed for the treatment of cancer has showed promise in treating blindness.

According to The Singapore Times, the drug PRL3-zumab was developed by the A*Star Institute of Molecular and Cell Biology (IMCB) and was created as a broad-spectrum anti-cancer drug that could treat not one but multiple types of cancer.

In a Singapore trial of the drug, patients with either wet age-related macular degeneration (AMD) or diabetic retinopathy will receive a shot of the medicine intravenously.

Globally, these two conditions are among the most common causes of loss of sight.

How does it work? According to pre-clinical studies published in Nature Communications as PRL3-zumab reduced leakage from damaged blood vessels...